Pharmacogenetics and human genetic polymorphisms

Biochemical Journal

Volumn 429, Issue 3, 2010, Pages 435-449

  Daly, Ann K ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Adverse drug reaction (ADR); Cytochrome P450; Genome wide association study; Human gene polymorphism; Human leucocyte antigen (HLA); Pharmacogenetics

Indexed keywords

ADVERSE DRUG REACTIONS; CYTOCHROME P450; GENOME-WIDE ASSOCIATION; HUMAN GENE POLYMORPHISM; LEUCOCYTE; PHARMACOGENETICS;

ACETYLATION; ANTIGENS; DRUG PRODUCTS; ENCODING (SYMBOLS); ENZYMES; GENES; ION EXCHANGE; PLANTS (BOTANY); POLYMORPHISM; REFRIGERATORS;

ASSOCIATION REACTIONS;

ABACAVIR; AMOXICILLIN PLUS CLAVULANIC ACID; CAFFEINE; CARBAMAZEPINE; CHLOROQUINE; CITALOPRAM; CLARITHROMYCIN; COTRIMOXAZOLE; COUMARIN; CYCLOPHOSPHAMIDE; EFAVIRENZ; ESCITALOPRAM; FLUCLOXACILLIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISONIAZID; MEPHENYTOIN; NICOTINE; NORTRIPTYLINE; OLANZAPINE; OMEPRAZOLE; PACLITAXEL; PENICILLAMINE; RETINOIC ACID; TAMOXIFEN; TERFENADINE; THIORIDAZINE; TICLOPIDINE; UNINDEXED DRUG; WARFARIN; XIMELAGATRAN;

BREAST CANCER; DRUG CONJUGATION; DRUG DISPOSITION; DRUG METABOLISM; DRUG OXIDATION; DRUG TRANSPORT; GENETIC POLYMORPHISM; GENOME; HUMAN; HYPERSENSITIVITY; LIVER TOXICITY; MUSCLE DISEASE; PHARMACOGENETICS; PRIORITY JOURNAL; QT PROLONGATION; RASH; REVIEW; SINGLE DRUG DOSE; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TOXIC HEPATITIS; GENETIC ASSOCIATION;

GENOME-WIDE ASSOCIATION STUDY; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 77955061641     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20100522     Document Type: Review

References (207)

1. Conti, A. and Bickel, M. H. (1977) History of drug metabolism: discoveries of major pathways in 19th century. Drug Metab. Rev. 6, 1-50
2. Meyer, U. A. (2004) Pharmacogenetics: five decades of therapeutic lessons from genetic diversity. Nat. Rev. Genet. 5, 669-676
3. Snyder, L. H. (1932) Studies in human inheritance IX. The inheritance of taste deficiency in man. Ohio J. Sci. 32, 436-468
4. Wooding, S. (2006) Phenylthiocarbamide: a 75-year adventure in genetics and natural selection. Genetics 172, 2015-2023
5. Clayman, C. B., Arnold, J., Hockwald, R. S., Yount, Jr, E. H., Edgcomb, J. H. and Alving, A. S. (1952) Toxicity of primaquine in Caucasians. J. Am. Med. Assoc. 149, 1563-1568
6. Alving, A. S., Carson, P. E., Flanagan, C. L. and Ickes, C. E. (1956) Enzymatic deficiency in primaquine-sensitive erythrocytes. Science 124, 484-485
7. Hirono, A. and Beutler, E. (1988) Molecular cloning and nucleotide sequence of cDNA for human glucose-6-phosphate dehydrogenase variant A-. Proc. Natl. Acad. Sci. U.S.A. 85, 3951-3954
8. Rieder, H. L. (2009) Fourth-generation fluoroquinolones in tuberculosis. Lancet 373, 1148-1149
9. Hughes, H. B. (1953) On the metabolic fate of isoniazid. J. Pharmacol. Exp. Ther. 109, 444-452
10. Hughes, H. B., Biehl, J. P., Jones, A. P. and Schmidt, L. H. (1954) Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis. Am. Rev. Tuberc. 70, 266-273
11. Mitchell, R. S. and Bell, J. C. (1957) Clinical implications of isoniazid, PAS and streptomycin blood levels in pulmonary tuberculosis. Trans. Am. Clin. Climatol. Assoc. 69, 98-105
12. Harris, H. W., Knight, R. A. and Selin, M. J. (1958) Comparison of isoniazid concentrations in the blood of people of Japanese and European descent; therapeutic and genetic implications. Am. Rev. Tuberc. 78, 944-948
13. Evans, D. A., Manley, K. A. and McKusick, K. V. (1960) Genetic control of isoniazid metabolism in man. Br. Med. J. 2, 485-491
14. Lehmann, H. and Ryan, E. (1956) The familial incidence of low pseudocholinesterase level. Lancet 271, 124
15. Kalow, W. (1990) The Pennsylvania State University College of Medicine 1990 Bernard B. Brodie lecture: Pharmacogenetics: past and future. Life Sci. 47, 1385-1397
16. Motulsky, A. G. (1957) Drug reactions enzymes, and biochemical genetics. J. Am. Med. Assoc. 165, 835-837
17. Vogel, F. (1959) Moderne probleme der humangenetik. Ergeb. Inn. Med. Kinderheild. 12, 52-62
18. Conney, A. H., Miller, E. C. and Miller, J. A. (1957) Substrate-induced synthesis and other properties of benzpyrene hydroxylase in rat liver. J. Biol. Chem. 228, 753-766
19. Brodie, B. B., Gillette, J. R. and La Du, B. N. (1958) Enzymatic metabolism of drugs and other foreign compounds. Annu. Rev. Biochem. 27, 427-454
20. Omura, T. and Sato, R. (1962) A new cytochrome in liver microsomes. J. Biol. Chem. 237, 1375-1376
21. Cooper, D. Y., Estabrook, R. W. and Rosenthal, O. (1963) The stoichiometry of C21 hydroxylation of steroids by adrenocortical microsomes. J. Biol. Chem. 238, 1320-1323
22. Cooper, D. Y., Levin, S., Narasimhulu, S. and Rosenthal, O. (1965) Photochemical action spectrum of the terminal oxidase of mixed function oxidase systems. Science 147, 400-402
23. Sladek, N. E. and Mannering, G. J. (1969) Induction of drug metabolism. I. Differences in the mechanisms by which polycyclic hydrocarbons and phenobarbital produce their inductive effects on microsomal N-demethylating systems. Mol. Pharmacol. 5, 174-185
24. Alvares, A. P., Schilling, G., Levin, W. and Kuntzman, R. (1967) Studies on the induction of CO-binding pigments in liver microsomes by phenobarbital and 3-methylcholanthrene. Biochem. Biophys. Res. Commun. 29, 521-526
25. Cheng, K. C. and Schenkman, J. B. (1982) Purification and characterization of two constitutive forms of rat liver microsomal cytochrome P-450. J. Biol. Chem. 257, 2378-2385
26. Wiebel, F. J., Selkirk, J. K., Gelboin, H. V., Haugen, D. A., van der Hoeven, T. A. and Coon, M. J. (1975) Position-specific oxygenation of benzo(a)pyrene by different forms of purified cytochrome P-450 from rabbit liver. Proc. Natl. Acad. Sci. U.S.A. 72, 3917-3920
27. Mahgoub, A., Idle, J. R., Dring, L. G., Lancaster, R. and Smith, R. L. (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet 2, 584-586
28. Eichelbaum, M., Spannbrucker, N., Steincke, B. and Dengler, H. J. (1979) Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur. J. Clin. Pharmacol. 17, 153-155
29. Bertilsson, L., Dengler, H. J., Eichelbaum, M. and Schulz, H. U. (1980) Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine. Eur. J. Clin. Pharmacol. 17, 153-155
30. Evans, D. A. P., Mahgoun, A., Sloan, T. P., Idle, J. R. and Smith, R. L. (1980) A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J. Med. Genet. 17, 102-105
31. Bertilsson, L., Eichelbaum, M., Mellstrom, B., Sawe, J., Schultz, N. V. and Sjoqvist, F. (1980) Nortryptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci. 27, 1673-1677
32. Kahn, G. C., Boobis, A. R., Murray, S., Brodie, M. J. and Davies, D. S. (1982) Assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver. Br. J. Clin. Pharmacol. 13, 637-645
33. Meier, P. J., Mueller, H. K., Dick, B. and Meyer, U. A. (1983) Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation. Gastroenterology 85, 682-692
34. Distelrath, L. M., Reilly, P. E. B., Martin, M. V., Davis, G. G., Wilkinson, G. R. and Guengerich, F. P. (1985) Purification and characterisation of the human liver cytochromes P450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 260, 9057-9067
35. Gonzalez, F. J., Vilbois, F., Hardwick, J. P., McBride, O. W., Nebert, D. W., Gelboin, H. V. and Meyer, U. A. (1988) Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2Dlocus to chromosome 22. Genomics 2, 174-179
36. Heim, M. and Meyer, U. A. (1990) Genotyping of poor metabolizers by allele-specific PCR amplification. Lancet 2, 529-532
37. Gough, A. C., Miles, J. S., Spurr, N. K., Moss, J. E., Gaedigk, A., Eichelbaum, M. and Wolf, C. R. (1990) Identification of the primary gene defect at the cytochrome P450 CYP2Dlocus. Nature 347, 773-776
38. Hanioka, N., Kimura, S., Meyer, U. A. and Gonzalez, F. J. (1990) The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934 to A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3′ splice recognition site. Am. J. Hum. Genet. 47, 994-1001
39. Kagimoto, M., Heim, M., Kagimoto, K., Zeugin, T. and Meyer, U. A. (1990) Multiple mutations of the human cytochrome P450IID6 gene ( CYP2D6) in poor metabolizers of debrisoquine. J. Biol. Chem. 265, 17209-17214
40. Gaedigk, A., Blum, M., Gaedigk, R., Eichelbaum, M. and Meyer, U. A. (1991) Deletion of the entire cytochrome P450 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am. J. Hum. Genet. 48, 943-950
41. Johansson, I., Lundqvist, E., Bertilsson, L., Dahl, M.-L., Sjoqvist, F. and Ingelman-Sundberg, M. (1993) Inherited amplification of an active gene in the cytochrome P450 CYP2Dlocus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. U.S.A. 90, 11825-11829
42. Kupfer, A. and Preisig, R. (1984) Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur. J. Clin. Pharmacol. 26, 753-759
43. de Morais, S. M. F., Wilkinson, G. R., Blaisdell, J., Meyer, U. A., Nakamura, K. and Goldstein, J. A. (1994) Identification of a new genetic defect responsible for the polymorphism of ( S)-mephenytoin metabolism in Japanese. Mol. Pharmacol. 46, 594-598
44. de Morais, S. M. F., Wilkinson, G. R., Blaisdell, J., Nakamura, K., Meyer, U. A. and Goldstein, J. A. (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem. 269, 15419-15422
45. Scott, J. and Poffenbarger, P. L. (1978) Pharmacogenetics of tolbutamide metabolism in humans. Diabetes 28, 41-51
46. Miners, J. O., Smith, K. J., Robson, R. A., McManus, M. E., Veronese, M. E. and Birkett, D. J. (1988) Tolbutamide hydroxylation by human liver microsomes: kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem. Pharmacol. 37, 1137-1144
47. Kimura, S., Pastewka, J., Gelboin, H. V. and Gonzalez, F. J. (1987) cDNA and amino acid sequences of two members of the human P450IIC gene subfamily. Nucleic Acids Res. 15, 10053-10054
48. Meehan, R. R., Gosden, J. R., Rout, D., Hastie, N. D., Friedberg, T., Adesnik, M., Buckland, R., van Heyningen, V., Fletcher, J., Spurr, N. K. et al. (1988) Human cytochrome P450 PB-1: a multigene family involved in mephenytoin and steroid oxidations that maps to chromosome 10. Am. J. Hum. Genet. 42, 26-37
49. Rettie, A. E., Wienkers, L. C., Gonzalez, F. J., Trager, W. F. and Korzekwa, K. R. (1994) Impaired ( S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 4, 39-42
50. Sullivan-Close, T. H., Ghanayem, B. I., Bell, D. A., Zhang, Z.-Y., Kaminsky, L. S., Shenfield, G. M., Miners, J. O., Birkett, D. J. and Goldstein, J. A. (1996) The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6, 341-349
51. Furuya, H., Fernandez-Salguero, P., Gregory, W., Taber, H., Steward, A., Gonzalez, F. J. and Idle, J. R. (1995) Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 5, 389-392
52. Steward, D. J., Haining, R. L., Henne, K. R., Davis, G., Rushmore, T. H., Trager, W. F. and Rettie, A. E. (1997) Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 7, 361-367
53. Aithal, G. P., Day, C. P., Kesteven, P. J. L. and Daly, A. K. (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353, 717-719
54. Eichelbaum, M., Ingelman-Sundberg, M. and Evans, W. E. (2006) Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 57, 119-137
55. Ingelman-Sundberg, M., Sim, S. C., Gomez, A. and Rodriguez-Antona, C. (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther. 116, 496-526
56. Zanger, U. M., Raimundo, S. and Eichelbaum, M. (2004) Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch. Pharmacol. 369, 23-37
57. Kirchheiner, J. and Brockmoller, J. (2005) Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Ther. 77, 1-16
58. Reference deleted
59. Rodriguez-Antona, C., Sayi, J. G., Gustafsson, L. L., Bertilsson, L. and Ingelman-Sundberg, M. (2005) Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles. Biochem. Biophys. Res. Commun. 338, 299-305
60. Zhang, B., Xie, W. and Krasowski, M. D. (2008) PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics 9, 1695-1709
61. Zhang, J., Kuehl, P., Green, E. D., Touchman, J. W., Watkins, P. B., Daly, A., Hall, S. D., Maurel, P., Relling, M., Brimer, C. et al. (2001) The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 11, 555-572
62. Daly, A. K. (2006) Significance of the minor cytochrome P450 3A isoforms. Clin. Pharmacokinet. 45, 13-31
63. Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S. A., Hall, S. D. et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27, 383-391
64. Sachse, C., Brockmoller, J., Bauer, S. and Roots, I. (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60, 284-295
65. Gaedigk, A., Simon, S. D., Pearce, R. E., Bradford, L. D., Kennedy, M. J. and Leeder, J. S. (2008) The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther. 83, 234-242
66. Shen, H., He, M. M., Liu, H., Wrighton, S. A., Wang, L., Guo, B. and Li, C. (2007) Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug Metab. Dispos. 35, 1292-1300
67. Toscano, C., Klein, K., Blievernicht, J., Schaeffeler, E., Saussele, T., Raimundo, S., Eichelbaum, M., Schwab, M. and Zanger, U. M. (2006) Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events. Pharmacogenet. Genomics 16, 755-766
68. Dahl, M. L., Johansson, I., Bertilsson, L., Ingelmansundberg, M. and Sjoqvist, F. (1995) Ultrarapid hydroxylation of debrisoquine in a swedish population: analysis of the molecular-genetic basis. J. Pharmacol. Exp. Ther. 274, 516-520
69. Lovlie, R., Daly, A. K., Molven, A., Idle, J. R. and Steen, V. M. (1996) Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett. 392, 30-34
70. Aklillu, E., Persson, I., Bertilsson, L., Johansson, I., Rodrigues, F. and Ingelman-Sundberg, M. (1996) Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J. Pharmacol. Exp. Ther. 278, 441-446
71. Dalen, P., Dahl, M. L., Bernal Ruiz, M. L., Nordin, J. and Bertilsson, L. (1998) 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3 and 13 functional CYP2D6 genes. Clin. Pharmacol. Ther. 63, 444-452
72. Kirchheiner, J., Brosen, K., Dahl, M. L., Gram, L. F., Kasper, S., Roots, I., Sjoqvist, F., Spina, E. and Brockmoller, J. (2001) CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr. Scand. 104, 173-192
73. Somogyi, A. A., Barratt, D. T. and Coller, J. K. (2007) Pharmacogenetics of opioids. Clin. Pharmacol. Ther. 81, 429-444
74. Gasche, Y., Daali, Y., Fathi, M., Chiappe, A., Cottini, S., Dayer, P. and Desmeules, J. (2004) Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N. Engl. J. Med. 351, 2827-2831
75. Koren, G., Cairns, J., Chitayat, D., Gaedigk, A. and Leeder, S. J. (2006) Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 368, 704 (Pubitemid 44223697)
76. Kirchheiner, J., Schmidt, H., Tzvetkov, M., Keulen, J. T., Lotsch, J., Roots, I. and Brockmoller, J. (2006) Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J. 7, 257-265
77. Madadi, P., Ross, C. J., Hayden, M. R., Carleton, B. C., Gaedigk, A., Leeder, J. S. and Koren, G. (2009) Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin. Pharmacol. Ther. 85, 31-35
78. He, Y. J., Brockmoller, J., Schmidt, H., Roots, I. and Kirchheiner, J. (2008) CYP2D6 ultrarapid metabolism and morphine/codeine ratios in blood: was it codeine or heroin? J. Anal. Toxicol. 32, 178-182
79. Desta, Z., Ward, B. A., Soukhova, N. V. and Flockhart, D. A. (2004) Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J. Pharmacol. Exp. Ther. 310, 1062-1075
80. Lim, Y. C., Li, L., Desta, Z., Zhao, Q., Rae, J. M., Flockhart, D. A. and Skaar, T. C. (2006) Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J. Pharmacol. Exp. Ther. 318, 503-512
81. Goetz, M. P., Rae, J. M., Suman, V. J., Safgren, S. L., Ames, M. M., Visscher, D. W., Reynolds, C., Couch, F. J., Lingle, W. L., Flockhart, D. A., Desta, Z., Perez, E. A. and Ingle, J. N. (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 23, 9312-9318
82. Jin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K. H., Skaar, T., Storniolo, A. M., Li, L., Araba, A. et al. (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl. Cancer Inst. 97, 30-39
83. Schroth, W., Goetz, M. P., Hamann, U., Fasching, P. A., Schmidt, M., Winter, S., Fritz, P., Simon, W., Suman, V. J., Ames, M. M. et al. (2009) Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA, J. Am. Med. Assoc. 302, 1429-1436
84. Scordo, M. G., Aklillu, E., Yasar, U., Dahl, M. L., Spina, E. and Ingelman-Sundberg, M. (2001) Genetic polymorphism of cytochrome P4502C9 in a Caucasian and a black African population. Br. J. Clin. Pharmacol. 52, 447-450
85. Solus, J. F., Arietta, B. J., Harris, J. R., Sexton, D. P., Steward, J. Q., McMunn, C., Ihrie, P., Mehall, J. M., Edwards, T. L. and Dawson, E. P. (2004) Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 5, 895-931
86. Daly, A. K. (2009) Pharmacogenomics of anticoagulants: steps toward personal dosage. Genome Med. 1, 10
87. Klein, T. E., Altman, R. B., Eriksson, N., Gage, B. F., Kimmel, S. E., Lee, M. T., Limdi, N. A., Page, D., Roden, D. M., Wagner, M. J. et al. (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360, 753-764
88. Goldstein, J. A. (2001) Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br. J. Clin. Pharmacol. 52, 349-355
89. Furuta, T., Ohashi, K., Kamata, T., Takashima, M., Kosuge, K., Kawasaki, T., Hanai, H., Kubota, T., Ishizaki, T. and Kaneko, E. (1998) Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann. Intern. Med. 129, 1027-1030
90. Simon, T., Verstuyft, C., Mary-Krause, M., Quteineh, L., Drouet, E., Meneveau, N., Steg, P. G., Ferrieres, J., Danchin, N. and Becquemont, L. (2009) Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360, 363-375
91. Shuldiner, A. R., O'Connell, J. R., Bliden, K. P., Gandhi, A., Ryan, K., Horenstein, R. B., Damcott, C. M., Pakyz, R., Tantry, U. S., Gibson, Q. et al. (2009) Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA, J. Am. Med. Assoc. 302, 849-857
92. Ellis, K. J., Stouffer, G. A., McLeod, H. L. and Lee, C. R. (2009) Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. Pharmacogenomics 10, 1799-1817
93. Sofi, F., Giusti, B., Marcucci, R., Gori, A. M., Abbate, R. and Gensini, G. F. (2010) Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis, Pharmacogenomics J., doi: 10.1038/tpj.2010.21
94. Desta, Z., Zhao, X., Shin, J. G. and Flockhart, D. A. (2002) Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet. 41, 913-958
95. Rudberg, I., Hendset, M., Uthus, L. H., Molden, E. and Refsum, H. (2006) Heterozygous mutation in CYP2C19 significantly increases the concentration/dose ratio of racemic citalopram and escitalopram (S-citalopram). Ther. Drug Monit. 28, 102-105 (Pubitemid 44391702)
96. Sim, S. C., Risinger, C., Dahl, M. L., Aklillu, E., Christensen, M., Bertilsson, L. and Ingelman-Sundberg, M. (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin. Pharmacol. Ther. 79, 103-113
97. Baldwin, R. M., Ohlsson, S., Pedersen, R. S., Mwinyi, J., Ingelman-Sundberg, M., Eliasson, E. and Bertilsson, L. (2008) Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br. J. Clin. Pharmacol. 64, 1175-1179
98. Rudberg, I., Mohebi, B., Hermann, M., Refsum, H. and Molden, E. (2008) Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin. Pharmacol. Ther. 83, 322-327
99. van Schie, R. M., Wadelius, M. I., Kamali, F., Daly, A. K., Manolopoulos, V. G., de Boer, A., Barallon, R., Verhoef, T. I., Kirchheiner, J., Haschke-Becher, E. et al. (2009) Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 10, 1687-1695
100. Weinshilboum, R. and Sladek, S. L. (1980) Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet. 32, 651-662
101. Seidegard, J. and Pero, R. W. (1985) The hereditary transmission of high glutathione transferase-activity towards trans-stilbene oxide in human mononuclear leukocytes. Hum. Genet. 69, 66-68
102. Gilbert, C. and Lereboullet, P. (1901) La cholemie simple familiale. Semaine Medicale 21, 241-243
103. Macklon, A. F., Savage, R. L. and Rawlins, M. D. (1979) Gilbert syndrome and drug metabolism. Clin. Pharmacokinet. 4, 223-232
104. Strassburg, C. P., Kalthoff, S. and Ehmer, U. (2008) Variability and function of family 1 uridine-5′-diphosphate glucuronosyltransferases (UGT1A). Crit. Rev. Clin. Lab. Sci. 45, 485-530
105. Seidegard, J., Vorachek, W. R., Pero, R. W. and Pearson, W. R. (1988) Hereditary differences in the expression of the human glutathione S -transferase active on trans-stilbene oxide are due to a gene deletion. Proc. Natl. Acad. Sci. U.S.A. 85, 7293-7297
106. Blum, M., Demierre, A., Grant, D. M., Heim, M. and Meyer, U. A. (1991) Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc. Natl. Acad. Sci. U.S.A. 88, 5237-5241
107. Vatsis, K. P., Martell, K. J. and Weber, W. W. (1991) Diverse point mutations in the human gene for polymorphic N-acetyltransferase. Proc. Natl. Acad. Sci. U.S.A. 88, 6333-6337
108. Hickman, D. and Sim, E. (1991) N-acetyltransferase polymorphism. Comparison of phenotype and genotype in humans. Biochem. Pharmacol. 42, 1007-1014
109. Szumlanski, C., Otterness, D., Her, C., Lee, D., Brandriff, B., Kelsell, D., Spurr, N., Lennard, L., Wieben, E. and Weinshilboum, R. (1996) Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol. 15, 17-30
110. Tai, H.-L., Krynetski, E. Y., Yates, C. R., Loennechen, T., Fessing, M. Y., Krynetskaia, N. F. and Evans, W. E. (1996) Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am. J. Hum. Genet. 58, 694-702
111. Monaghan, G., Ryan, M., Seddon, R., Hume, R. and Burchell, B. (1996) Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 347, 578-581
112. Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H. P., Brockmoller, J., Johne, A., Cascorbi, I., Gerloff, T., Roots, I., Eichelbaum, M. and Brinkmann, U. (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. U.S.A. 97, 3473-3478
113. Chinn, L. W. and Kroetz, D. L. (2007) ABCB1 pharmacogenetics: progress, pitfalls, and promise. Clin. Pharmacol. Ther. 81, 265-269
114. Suzuki, H. and Sugiyama, Y. (2002) Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Adv. Drug Deliv. Rev. 54, 1311-1331
115. Wagner, M., Zollner, G. and Trauner, M. (2009) New molecular insights into the mechanisms of cholestasis. J. Hepatol. 51, 565-580
116. Kalliokoski, A. and Niemi, M. (2009) Impact of OATP transporters on pharmacokinetics. Br. J. Pharmacol. 158, 693-705
117. Shu, Y., Sheardown, S. A., Brown, C., Owen, R. P., Zhang, S., Castro, R. A., Ianculescu, A. G., Yue, L., Lo, J. C., Burchard, E. G. et al. (2007) Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J. Clin. Invest. 117, 1422-1431
118. Filipski, K. K., Mathijssen, R. H., Mikkelsen, T. S., Schinkel, A. H. and Sparreboom, A. (2009) Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin. Pharmacol. Ther. 86, 396-402
119. Hawkins, G. A., Weiss, S. T. and Bleecker, E. R. (2008) Clinical consequences of ADRβ2 polymorphisms. Pharmacogenomics 9, 349-358
120. D'Souza, U. M. and Craig, I. W. (2008) Functional genetic polymorphisms in serotonin and dopamine gene systems and their significance in behavioural disorders. Prog. Brain Res. 172, 73-98
121. Mason, D. A., Moore, J. D., Green, S. A. and Liggett, S. B. (1999) A gain-of-function polymorphism in a G-protein coupling domain of the human β1-adrenergic receptor. J. Biol. Chem. 274, 12670-12674
122. Belfer, I., Buzas, B., Evans, C., Hipp, H., Phillips, G., Taubman, J., Lorincz, I., Lipsky, R. H., Enoch, M. A., Max, M. B. and Goldman, D. (2005) Haplotype structure of the β adrenergic receptor genes in US Caucasians and African Americans. Eur. J. Hum. Genet. 13, 341-351
123. Brodde, O. E. (2008) β-1 and β-2 adrenoceptor polymorphisms: functional importance, impact on cardiovascular diseases and drug responses. Pharmacol. Ther. 117, 1-29
124. Drysdale, C. M., McGraw, D. W., Stack, C. B., Stephens, J. C., Judson, R. S., Nandabalan, K., Arnold, K., Ruano, G. and Liggett, S. B. (2000) Complex promoter and coding region β 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc. Natl. Acad. Sci. U.S.A. 97, 10483-10488
125. Green, S. A., Turki, J., Innis, M. and Liggett, S. B. (1994) Amino-terminal polymorphisms of the human β 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 33, 9414-9419
126. Collins, S., Caron, M. G. and Lefkowitz, R. J. (1992) From ligand binding to gene expression: new insights into the regulation of G-protein-coupled receptors. Trends Biochem. Sci. 17, 37-39
127. Chong, L. K., Chowdry, J., Ghahramani, P. and Peachell, P. T. (2000) Influence of genetic polymorphisms in the β2-adrenoceptor on desensitization in human lung mast cells. Pharmacogenetics 10, 153-162
128. 2-adrenergic receptor gene and desensitization in human airway smooth muscle. Am. J. Respir. Crit. Care Med. 162, 2117-2124
129. 2 adrenoceptor polymorphism. Thorax 55, 762-767
130. Israel, E., Chinchilli, V. M., Ford, J. G., Boushey, H. A., Cherniack, R., Craig, T. J., Deykin, A., Fagan, J. K., Fahy, J. V., Fish, J. et al. (2004) Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 364, 1505-1512
131. Bleecker, E. R., Postma, D. S., Lawrance, R. M., Meyers, D. A., Ambrose, H. J. and Goldman, M. (2007) Effect of ADRB2 polymorphisms on response to longacting β2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 370, 2118-2125
132. de Groote, P., Helbecque, N., Lamblin, N., Hermant, X., Mc Fadden, E., Foucher-Hossein, C., Amouyel, P., Dallongeville, J. and Bauters, C. (2005) Association between β-1 and β-2 adrenergic receptor gene polymorphisms and the response to β-blockade in patients with stable congestive heart failure. Pharmacogenet. Genomics 15, 137-142
133. Sehnert, A. J., Daniels, S. E., Elashoff, M., Wingrove, J. A., Burrow, C. R., Horne, B., Muhlestein, J. B., Donahue, M., Liggett, S. B., Anderson, J. L. and Kraus, W. E. (2008) Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. J. Am. Coll. Cardiol. 52, 644-651
134. Pacanowski, M. A., Gong, Y., Cooper-Dehoff, R. M., Schork, N. J., Shriver, M. D., Langaee, T. Y., Pepine, C. J. and Johnson, J. A. (2008) β-adrenergic receptor gene polymorphisms and β-blocker treatment outcomes in hypertension. Clin. Pharmacol. Ther. 84, 715-721
135. O'Reilly, R. A. (1970) The second reported kindred with hereditary resistance to oral anticoagulant drugs. N. Engl. J. Med. 282, 1448-1451
136. Rost, S., Fregin, A., Ivaskevicius, V., Conzelmann, E., Hortnagel, K., Pelz, H. J., Lappegard, K., Seifried, E., Scharrer, I., Tuddenham, E. G. D. et al. (2004) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427, 537-541
137. Li, T., Chang, C. Y., Jin, D. Y., Lin, P. J., Khvorova, A. and Stafford, D. W. (2004) Identification of the gene for vitamin K epoxide reductase. Nature 427, 541-544
138. D'Andrea, G., D'Ambrosio R, L., Di Perna, P., Chetta, M., Santacroce, R., Brancaccio, V., Grandone, E. and Margaglione, M. (2005) A polymorphism in VKORC1gene is associated with an inter-individual variability in the dose-anticoagulant effect of warfarin. Blood 105, 645-649 (Pubitemid 40070748)
139. Rieder, M. J., Reiner, A. P., Gage, B. F., Nickerson, D. A., Eby, C. S., McLeod, H. L., Blough, D. K., Thummel, K. E., Veenstra, D. L. and Rettie, A. E. (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352, 2285-2293
140. Sconce, E. A., Khan, T. I., Wynne, H. A., Avery, P., Monkhouse, L., King, B. P., Wood, P., Kesteven, P., Daly, A. K. and Kamali, F. (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106, 2329-2333
141. Jonas, D. E. and McLeod, H. L. (2009) Genetic and clinical factors relating to warfarin dosing. Trends Pharmacol. Sci. 30, 375-386
142. Goldstein, J. L. and Brown, M. S. (1990) Regulation of the mevalonate pathway. Nature 343, 425-430
143. Chasman, D. I., Posada, D., Subrahmanyan, L., Cook, N. R., Stanton, Jr, V. P. and Ridker, P. M. (2004) Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA, J. Am. Med. Assoc. 291, 2821-2827
144. Krauss, R. M., Mangravite, L. M., Smith, J. D., Medina, M. W., Wang, D., Guo, X., Rieder, M. J., Simon, J. A., Hulley, S. B., Waters, D. et al. (2008) Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation 117, 1537-1544
145. Thompson, J. F., Man, M., Johnson, K. J., Wood, L. S., Lira, M. E., Lloyd, D. B., Banerjee, P., Milos, P. M., Myrand, S. P., Paulauskis, J. et al. (2005) An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J. 5, 352-358
146. Singer, J. B., Holdaas, H., Jardine, A. G., Fellstrom, B., Os, I., Bermann, G. and Meyer, J. M. (2007) Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. J. Lipid Res. 48, 2072-2078
147. Polisecki, E., Muallem, H., Maeda, N., Peter, I., Robertson, M., McMahon, A. D., Ford, I., Packard, C., Shepherd, J., Jukema, J. W. et al. (2008) Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. Atherosclerosis 200, 109-114
148. Donnelly, L. A., Doney, A. S., Dannfald, J., Whitley, A. L., Lang, C. C., Morris, A. D., Donnan, P. T. and Palmer, C. N. (2008) A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study. Pharmacogenet. Genomics 18, 1021-1026
149. Jeunemaitre, X. (2008) Genetics of the human renin angiotensin system. J. Mol. Med. 86, 637-641
150. Halushka, M. K. and Halushka, P. V. (2006) Toward individualized analgesic therapy: functional cyclooxygenase 1 and 2 haplotypes. Clin. Pharmacol. Ther. 79, 404-406
151. Rawlins, M. D. and Thompson, J. W. (1991) Mechanisms of adverse drug reactions. In Textbook of Adverse Drug Reactions (Davies, D. M., ed.), pp. 18-45, Oxford University Press, Oxford
152. Pirmohamed, M., Breckenridge, A. M., Kitteringham, N. R. and Park, B. K. (1998) Adverse drug reactions. Br. Med. J. 316, 1295-1298
153. Lee, W. M. (2003) Medical progress: drug-induced hepatotoxicity. N. Engl. J. Med. 349, 474-485
154. Hautekeete, M. L., Horsmans, Y., van Waeyenberge, C., Demanet, C.,
155. O'Donohue, J., Oien, K. A., Donaldson, P., Underhill, J., Clare, M., MacSween, R. M. and Mills, P. R. (2000) Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 47, 717-720
156. Daly, A. K., Donaldson, P. T., Bhatnagar, P., Shen, Y., Pe'er, I., Floratos, A., Daly, M. J., Goldstein, D. B., John, S., Nelson, M. R. et al. (2009) HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet. 41, 816-819
157. Mallal, S., Nolan, D., Witt, C., Masel, G., Martin, A. M., Moore, C., Sayer, D., Castley, A., Mamotte, C., Maxwell, D. et al. (2002) Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse transcriptase inhibitor abacavir. Lancet 359, 727-732
158. Kindmark, A., Jawaid, A., Harbron, C. G., Barratt, B. J., Bengtsson, O. F., Andersson, T. B., Carlsson, S., Cederbrant, K. E., Gibson, N. J., Armstrong, M. et al. (2008) Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 8, 186-195
159. Hirata, K., Takagi, H., Yamamoto, M., Matsumoto, T., Nishiya, T., Mori, K., Shimizu, S., Masumoto, H. and Okutani, Y. (2008) Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J. 8, 29-33
160. Hetherington, S., McGuirk, S., Powell, G., Cutrell, A., Naderer, O., Spreen, B., Lafon, S., Pearce, G. and Steel, H. (2001) Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin. Ther. 23, 1603-1614
161. Hetherington, S., Hughes, A. R., Mosteller, M., Shortino, D., Baker, K. L., Spreen, W., Lai, E., Davies, K., Handley, A., Dow, D. J. et al. (2002) Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359, 1121-1122
162. Hughes, A. R., Mosteller, M., Bansal, A. T., Davies, K., Haneline, S. A., Lai, E. H., Nangle, K., Scott, T., Spreen, W. R., Warren, L. L. and Roses, A. D. (2004) Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 5, 203-211
163. Hughes, D. A., Vilar, F. J., Ward, C. C., Alfirevic, A., Park, B. K. and Pirmohamed, M. (2004) Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 14, 335-342
164. Mallal, S., Phillips, E., Carosi, G., Molina, J. M., Workman, C., Tomazic, J., Jagel-Guedes, E., Rugina, S., Kozyrev, O., Cid, J. F. et al. (2008) HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358, 568-579
165. Vittorio, C. C. and Muglia, J. J. (1995) Anticonvulsant hypersensitivity syndrome. Arch. Intern. Med. 155, 2285-2290
166. Leeder, J. S. (1998) Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs. Epilepsia 39 (Suppl. 7), S8-S16 (Pubitemid 28485582)
167. Rzany, B., Correia, O., Kelly, J. P., Naldi, L., Auquier, A. and Stern, R. (1999) Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Lancet 353, 2190-2194
168. Chung, W. H., Hung, S. I., Hong, H. S., Hsih, M. S., Yang, L. C., Ho, H. C., Wu, J. Y. and Chen, Y. T. (2004) Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428, 486
169. Locharernkul, C., Loplumlert, J., Limotai, C., Korkij, W., Desudchit, T., Tongkobpetch, S., Kangwanshiratada, O., Hirankarn, N. et al. (2008) Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 49, 2087-2091
170. Alfirevic, A., Jorgensen, A. L., Williamson, P. R., Chadwick, D. W., Park, B. K. and Pirmohamed, M. (2006) HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 7, 813-818
171. Lonjou, C., Thomas, L., Borot, N., Ledger, N., de Toma, C., LeLouet, H., Graf, E., Schumacher, M., Hovnanian, A., Mockenhaupt, M. and Roujeau, J. C. (2006) A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J. 6, 265-268
172. Kaniwa, N., Saito, Y., Aihara, M., Matsunaga, K., Tohkin, M., Kurose, K., Sawada, J., Furuya, H., Takahashi, Y., Muramatsu, M. et al. (2008) HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 9, 1617-1622
173. Link, E., Parish, S., Armitage, J., Bowman, L., Heath, S., Matsuda, F., Gut, I., Lathrop, M. and Collins, R. (2008) SLCO1B1 variants and statin-induced myopathy-a genomewide study. N. Engl. J. Med. 359, 789-799
174. Voora, D., Shah, S. H., Spasojevic, I., Ali, S., Reed, C. R., Salisbury, B. A. and Ginsburg, G. S. (2009) The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J. Am. Coll. Cardiol. 54, 1609-1616
175. Niemi, M. (2010) Transporter pharmacogenetics and statin toxicity. Clin. Pharmacol. Ther. 87, 130-133
176. Kannankeril, P. J. and Roden, D. M. (2007) Drug-induced long QT and torsade de pointes: recent advances. Curr. Opin. Cardiol. 22, 39-43
177. Nishio, Y., Makiyama, T., Itoh, H., Sakaguchi, T., Ohno, S., Gong, Y. Z., Yamamoto, S., Ozawa, T., Ding, W. G., Toyoda, F. et al. (2009) D85N, a KCNE1 polymorphism, is a disease-causing gene variant in long QT syndrome. J. Am. Coll. Cardiol. 54, 812-819
178. Daly, A. K. (2010) Genome-wide association studies in pharmacogenomics. Nat. Rev. Genet. 11, 241-246
179. McCarthy, M. I., Abecasis, G. R., Cardon, L. R., Goldstein, D. B., Little, J., Ioannidis, J. P. and Hirschhorn, J. N. (2008) Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat. Rev. Genet. 9, 356-369
180. Wellcome Trust Case Control Consortium (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447, 661-678
181. Cooper, G. M., Johnson, J. A., Langaee, T. Y., Feng, H., Stanaway, I. B., Schwarz, U. I., Ritchie, M. D., Stein, C. M., Roden, D. M., Smith, J. D. et al. (2008) A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112, 1022-1027
182. Takeuchi, F., McGinnis, R., Bourgeois, S., Barnes, C., Eriksson, N., Soranzo, N., Whittaker, P., Ranganath, V., Kumanduri, V., McLaren, W. et al. (2009) A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5, e1000433
183. Tanaka, Y., Nishida, N., Sugiyama, M., Kurosaki, M., Matsuura, K., Sakamoto, N., Nakagawa, M., Korenaga, M., Hino, K., Hige, S. et al. (2009) Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41, 1105-1109
184. Suppiah, V., Moldovan, M., Ahlenstiel, G., Berg, T., Weltman, M., Abate, M. L., Bassendine, M., Spengler, U., Dore, G. J., Powell, E., Riordan, S. et al. (2009) IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat. Genet. 41, 1100-1104
185. Ge, D., Fellay, J., Thompson, A. J., Simon, J. S., Shianna, K. V., Urban, T. J., Heinzen, E. L., Qiu, P., Bertelsen, A. H., Muir, A. J. et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399-401
186. Sarasquete, M. E., Garcia-Sanz, R., Marin, L., Alcoceba, M., Chillon, M. C., Balanzategui, A., Santamaria, C., Rosinol, L., de la Rubia, J., Hernandez, M. T. et al. (2008) Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood 112, 2709-2712
187. Fleming, I. (2004) Cytochrome P450 epoxygenases as EDHF synthase(s). Pharmacol. Res. 49, 525-533
188. Nasirikenari, M., Segal, B. H., Ostberg, J. R., Urbasic, A. and Lau, J. T. (2006) Altered granulopoietic profile and exaggerated acute neutrophilic inflammation in mice with targeted deficiency in the sialyltransferase ST6Gal I. Blood 108, 3397-3405
189. Marshall, A. (1997) Laying the foundations for personalized medicines. Nat. Biotechnol. 15, 954-957
190. Daly, A. K. (2003) Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam. Clin. Pharmacol. 17, 27-41
191. Wang, H. and Tompkins, L. M. (2008) CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr. Drug Metab. 9, 598-610
192. Zanger, U. M., Klein, K., Saussele, T., Blievernicht, J., Hofmann, M. H. and Schwab, M. (2007) Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics 8, 743-759 (Pubitemid 47288975)
193. Totah, R. A. and Rettie, A. E. (2005) Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin. Pharmacol. Ther. 77, 341-352
194. Van Booven, D., Marsh, S., McLeod, H., Carrillo, M. W., Sangkuhl, K., Klein, T. E. and Altman, R. B. Cytochrome P450 2C9-CYP2C9. Pharmacogenet. Genomics 20, 277-281
195. Kirchheiner, J. and Seeringer, A. (2007) Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim. Biophys. Acta 1770, 489-494
196. Owen, R. P., Sangkuhl, K., Klein, T. E. and Altman, R. B. (2009) Cytochrome P450 2D6. Pharmacogenet. Genomics. 19, 559-562
197. Perera, M. A. (2010) The missing linkage: what pharmacogenetic associations are left to find in CYP3A? Expert Opin. Drug Metab. Toxicol. 6, 17-28
198. Wojnowski, L. and Kamdem, L. K. (2006) Clinical implications of CYP3A polymorphisms. Expert Opin. Drug Metab. Toxicol. 2, 171-182
199. Nagar, S. and Blanchard, R. L. (2006) Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan. Drug Metab. Rev. 38, 393-409
200. Miners, J. O., McKinnon, R. A. and Mackenzie, P. I. (2002) Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. Toxicology 181-182, 453-456
201. Hein, D. W. (2009) N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine. Expert Opin. Drug Metab. Toxicol. 5, 353-366
202. Sim, E., Lack, N., Wang, C. J., Long, H., Westwood, I., Fullam, E. and Kawamura, A. (2008) Arylamine N-acetyltransferases: structural and functional implications of polymorphisms. Toxicology 254, 170-183
203. Marsh, S. and Van Booven, D. J. (2009) The increasing complexity of mercaptopurine pharmacogenomics. Clin. Pharmacol. Ther. 85, 139-141
204. Daly, A. K. and Day, C. P. (2009) Genetic association studies in drug-induced liver injury. Semin. Liver Dis. 29, 400-411
205. Alfirevic, A. and Pirmohamed, M. Drug-induced hypersensitivity reactions and pharmacogenomics: past, present and future. Pharmacogenomics 11, 497-499
206. Peters, B. J., Klungel, O. H., Visseren, F. L., de Boer, A. and Maitland-van der Zee, A. H. (2009) Pharmacogenomic insights into treatment and management of statin-induced myopathy. Genome Med. 1, 120
207. Lerch, M. and Pichler, W. J. (2004) The immunological and clinical spectrum of delayed drug-induced exanthems. Curr. Opin. Allergy Clin. Immunol. 4, 411-419